Taro CFO departs

HAWTHORNE, N.Y. — Taro Pharmaceuticals announced late Tuesday that its CFO, Michael Kalb, had resigned his position to become CFO at another publicly traded company, effective June 29. Taro noted that Kalb’s departure was not the result of a dispute or disagreement with the company, including anything having to do with its accounting practices or financial reporting. 

 

“On behalf of the company, we want to thank Mike for his many contributions to the company during his seven-year tenure at Taro, including his leadership of Taro’s finance team and our listing on the New York Stock Exchange,” Taro CEO Kal Sundaram said. “We wish him continued success in his new position.”

 

Taro said it had begun an external search for Kalb’s successor.